Skip to main content
. 2016 Jul 20;7(32):52392–52403. doi: 10.18632/oncotarget.10721

Figure 3. MARVELD1 modulate gefitinib sensitivity.

Figure 3

A. A549 cells transfected with NC-siRNA or MARVELD1-siRNA were incubated with gefitinib in the presence of indicated SREBP inhibitor. Relative cell viability was measured after 48h. Interference of MARVELD1 enhances gefitinib sensitivity, and the potentiating effects were attenuated in the presence of SREBP inhibitor. B. Effects of overexpressing MARVELD1 (or empty vector as the control) on the sensitivity of cisplatin, paclitaxel or gefitinib in A549 cells were analyzed as above. C. Effects of MARVELD1 interference (or siRNA-NC as the control) on the sensitivity of cisplatin, paclitaxel or gefitinib in A549 cells were analyzed as above. D. Effects of SREBP inhibitors incubation (or PBS as the control) on the sensitivity of gefitinib, paclitaxel and cisplatin in A549 cells were analyzed as above. Data are means ± SD (n = 3). *P < 0.05.